Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
XpresTest Secures Nearly $40 Million in Contracts to Screen for Ebola at U.S. Airports and Abroad.
Nov 09, 2026
Contract Type
contract
BiotechnologyHealth Care
Description
The Trump administration awarded XpresTest nearly $40 million for contracts related to Ebola screening and outbreak response. These contracts mark a significant increase in the company's governmental funding, aimed at preventing disease spread in the U.S. and addressing outbreaks in the Democratic Republic of Congo.
Company Information
Company
XpresTest
About
XpresTest is a biosecurity company specializing in disease screening. It has experience in monitoring for COVID-19 and other diseases at U.S. airports. The company is a subsidiary of XWELL, which also offers spa services. XpresTest is venturing into new territory with international contracts.